T cell receptor delta joining 2 (TRDJ2)

T cell receptor delta joining 2 (TRDJ2) is one of the joining (J) gene segments found in the delta locus of the T cell receptor (TCR) in humans[7]. During the development of γδ T cells, TRDJ2 segments recombine with variable (V) and diversity (D) segments to generate the highly variable antigen-binding region of the TCR delta chain[3]. This process is essential for the diversity of the T cell repertoire that recognizes various antigens in the immune response. TRDJ2 is not a protein receptor, enzyme, or transporter; it is a DNA segment utilized in somatic recombination, similar to other J segments in immunoglobulin and T cell receptor loci. If a receptor target is required, the correct full molecule name would be "T cell receptor delta chain" or more specifically, "T cell receptor gamma-delta (γδ TCR)," which is the receptor formed after TRDJ2 and other segments recombine to generate the functional protein[1][3][7]. There is no evidence that TRDJ2 itself is a recognized therapeutic target or directly associated with disease, nor are there drugs or safety concerns attributed to it. Your query likely refers to a gene segment rather than a canonical therapeutic target.

Other names

TRDJ2

Not applicable; TRDJ2 does not encode a protein that is targeted by drugs.